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Background
Chromosome 22q11.2 deletion syndrome (22qDS) is the second 
most commonly occurring genetic syndrome (after trisomy 21) and 
is the most common microdeletion syndrome. The overall incidence 
is approximately 1 in 4 000 live births.[1] However, this figure might 
be an underestimate owing to the high rate of perinatal deaths 
secondary to severe congenital cardiac defects.[2,3] Whilst the vast 
majority of probands have a de novo microdeletion of chromosome 
22q11.2, about 10 - 15% of those affected inherit the 22q11.2 deletion 
from a parent with an autosomal dominant pattern of inheritance. 
Male and female genders are affected equally.[4,5]
This syndrome, with its broad range of phenotypic features (and 
previously known by many names), was at one stage thought to be 
different disease entities. Research has since confirmed a common 
underlying defect: a microdeletion of a segment (at 11.2) on the long 
arm (q) of chromosome 22[4-7] – hence 22qDS.
The deletion contains numerous genes, but linkage analysis has 
identified a smaller, so-called critical region containing at least 25 - 
30 candidate genes. This is known as the Di George critical region. 
The typically deleted region (TDR) is usually 3Mb in size, which 
encompasses about 30 genes. These typical deletions occur in the 
majority of cases (90%).[2,6] However, smaller deletions of less than 
1.5Mb have also been noted in 8% of cases, usually occurring distally 
to the TDR. The clinical severity of the syndrome has no correlation 
with the size of the deletion, and the reason for its wide phenotypic 
variability remains unclear.[2,5-6]
As the most phenotypically diverse syndrome, more than 180 
different abnormal features are associated with it.[8] The clinical 
features with which affected individuals present can vary greatly and 
include congenital heart disease (CHD) in 80%,[9] palatal abnormalities, 
characteristic facial features, developmental delay and learning 
difficulties. As many as 77% of individuals suffer an immune deficiency 
regardless of their clinical presentation. Autoimmune disease is not 
infrequent, occurring in 10 - 20% of patients.[8] Other common 
findings include hypocalcaemia, feeding problems, renal anomalies, 
hearing loss, laryngotracheo-oesophageal anomalies, seizures, skeletal 
abnormalities, neuropsychiatric disease and several malignancies. [3,4] 
Owing to this diversity, a diagnosis in one field warrants careful 
Predicted v. real prevalence of the 22q11.2 deletion 
syndrome in children with congenital heart disease 
presenting to Red Cross War Memorial Children’s 
Hospital, South Africa: A prospective study
R de Decker,1 MSc, MB ChB, DCH, FCPaeds (SA), Cert Med Genet (Paeds); Z Bruwer,2,3 MSc, PhD; L Hendricks,1 MB ChB, DCH, FCPaed (SA); 
M Schoeman,2,4 MSc; G Schutte,2,5 NDip, BTech; J Lawrenson,6 MB BCh, FCP (SA), MMed (Int)
1  Department of Paediatrics and Child Health, University of Cape Town and Red Cross War Memorial Children’s Hospital, Cape Town, South Africa
2  Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town,  
South Africa
3  Genetic and Developmental Medicine Clinic, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
4 Division of Molecular Biology and Human Genetics, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
5 Cytogenetics Laboratory, National Health Laboratory Service, Cape Town, South Africa
6  Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Children’s Hospital, Cape Town, South Africa
Corresponding author: R de Decker (rik.dedecker@uct.ac.za)
Background. The 22q11.2 deletion syndrome (22qDS) has more than 180 associated phenotypic features, yet genotype-phenotype 
correlation remains obscure. Since many of the clinical characteristics are serious, yet treatable (including congenital heart disease), 
clinicians must maintain a high index of clinical suspicion to recognise a suite of co-occurring phenotypic features that suggest a diagnosis 
of 22qDS. Óskarsdottir’s scoring schedule (the ‘O score’) is generally used to suggest the need for confirmatory fluorescent in situ 
hybridisation (FISH) testing, using the TUPLE 1 probe. An O score of two or more indicates the need for FISH testing. 
Objectives. A previous audit of FISH-positive results of patients with congenital heart disease at Red Cross War Memorial Children’s 
Hospital (RCWMCH) revealed a clinical recognition rate of 1.7%. However, we were concerned that the syndrome may be under-recognised 
in our setting. Our aims were therefore to assess the predictive value of ‘O scoring’ and to accurately determine the prevalence of 22qDS in 
our patient population. 
Methods. A prospective trial of FISH testing every new patient with congenital heart disease presenting to RCWMCH was undertaken to 
accurately determine the prevalence of 22qDS. The results were then compared with the ability of the O score to indicate the need for FISH testing.
Results. Testing of 125 patients detected deletions in six (4.8%, 2.8 times the previously determined clinical detection rate), thereby 
vindicating our concern that 22qDS is under-diagnosed. Of these 125 patients, 37 had an O score of 2 or 3, yet only 6 were FISH-positive, 
giving the O score a positive predictive value of only 14%. 
Conclusion. Until a more robust alternative recognition tool is available, South African clinicians should use all clinical recognition criteria 
liberally to suggest the need for formal testing for 22qDS.
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investigation for other ab norm alities, but 
only after confirmatory fluor escent in situ 
hybridisation (FISH) testing.
Testing for 22qDS
The presence of the typical deletion of 22qDS 
is confirmed by FISH testing. The two 
probes commercially available for 22q11.2 
FISH analysis are TUPLE1 and N25. The 
detection rate of FISH analysis using either 
probe is thought to be equivalent; however, 
FISH using either one of these probes is not 
sensitive enough to detect smaller deletions 
(<40kb) within the 22q11.2 region.[7]
Alternatives to FISH testing are now 
available, including multiplex ligation-
dependent probe amplification (MLPA), 
array comparative genomic hybridisation 
(CGH) and single nucleotide polymorphism 
(SNP) arrays.[12,13] Although these methods 
are more expensive, they have advantages 
in terms of turnaround time and detection 
rates.[12-15]
Owing to the broad spectrum of disease 
presentation in individuals with 22qDS, 
and because many clinical characteristics 
are treatable, it is imperative that clinicians 
maintain a high index of suspicion. In 2005, 
a study done in Sweden by Óskarsdottir 
et al.[14] of 100 FISH-positive children and 
adolescents ascertained the most common 
clinical features associated with 22qDS. 
Based on this information, they developed a 
scoring schedule (here referred to as the ‘O 
score’), suggesting that a score of more than 
2 (out of a total of 8) implied the need for 
confirmatory FISH testing (Table 1).
Recognising 22qDS in South Africa
Recognition of patients with 22qDS in 
our service may be difficult for two main 
reasons: the first is the difference in the 
facial dysmorphism of white and non-
white patients confirmed to have 22qDS. 
While nearly all white and many non-white 
patients have distinctive facial dysmorph-
ism to suggest the diagnosis, most of our 
non-white patients have extremely subtle 
facial dysmorphism of the syndrome, if 
any at all (Fig. 2). The second reason is 
that the phenotypic spectrum of 22qDS is 
extremely diverse,[3] including any of a set 
of 15 CHD diagnoses,[4] of which, previously 
at our institution, only truncus arteriosus 
was mistakenly perceived to be indicative 
of a diagnosis of 22qDS. Consequently, we 
were concerned that (possibly owing to an 
institutional bias) the cohort of patients 
positively identified with 22qDS at the Red 
Cross War Memorial Children’s Hospital 
(RCWMCH) under-represented its true 
prevalence. 
Assessing the prevalence at 
RCWMCH
The worldwide incidence of all CHD is said 
to be 8:1 000, but it is known to be higher in 
developing countries, and an incidence of 
1% seems more realistic.[1] The population 
incidence of 22qDS is estimated to be 1:4 000 
newborns,[15] therefore the fraction of 22qDS 
in a large random cohort of all newborn 
children with CHD should be around 1:50, 
or 2.0%. Approximately 80% of children 
born with 22qDS will have CHD,[8,9] so the 
prevalence of 22qDS in a random cohort 
of children with CHD at birth should be 
approximately 1.6%.
In 2006, we audited our FISH-positive 
22qDS results and found a clinical 
recognition rate of 1.7% (18 FISH-positive 
tests in 1 048 patients that had been newly 
diagnosed with CHD (data presented at 
the SA Heart Annual Congress in 2006). 
However, for several reasons, to assess the 
real prevalence in any cohort it must be 
determined prospectively; that is what this 
study aimed to do. 
Objectives
The present study was designed to determine 
accurately the prevalence of 22qDS in a 
cohort of children with CHD presenting 
to the cardiac services at RCWMCH. 
Furthermore, since we were using an 
international scoring system[12] to suggest 
FISH testing, we wanted to test its predictive 
value in our patient population.
To determine the true prevalence of 22qDS 
in patients presenting to our cardiac service, 
we recruited patients prospectively and FISH 
tested all children with significant CHD. 
Clearly, this approach will underestimate the 
birth incidence of 22qDS, since it does not 
take into account patients without CHD, as 
well as those who had died before presenting, 
or those who had not been clinically 
recognised and referred yet. The objective of 
the study, however, was to determine what our 
clinical pick-up rate should actually be and if 
it differed from our previously determined 
prevalence rate of 1.7%. 
Methods
A hospital-based prospective study was 
undertaken by recruiting all newly referred 
patients with a significant cardiac lesion 
presenting to the cardiology service at 
RCWMCH during a 7.5-month period. 
RCWMCH is the largest paediatric tertiary 
hospital in southern Africa and (together 
with the Tygerberg Children’s Hospital) 
forms part of the Paediatric Cardiac Service 
of the Western Cape (PCSWC) of South 
Africa. All cardiac surgery and cardiac 
catheterisations in the PCSWC are done at 
RCWMCH. Patients with acquired heart 
disease, neonates with isolated patent 
ductus arteriosus or cases with identifiable 
cardiogenetic syndromes (e.g. Down syn-
drome) were excluded from the study. 
Parents of the affected children were 
approached by a genetic counsellor and 
invited to participate in the research study 
for which written informed consent was 
obtained. In the event that a parent was not 
accessible, consent was also considered from 
the legal guardian. The hospital records 
of each enrolled patient were reviewed for 
notes or comments on dysmorphic features, 
extracardiac anomalies, or any other features 
Table 1. Diagnostic guidelines for consideration of genetic testing for 22qDS* 
Age period
Infant Preschool Childhood - adolescence
1 Cardiac defect Cardiac defect Cardiac defect
2 Thymic hypoplasia
Immunodeficiency
Recurrent infections Recurrent infections
Autoimmunity
3 Hypocalcaemia Hypoparathyroidism Hypoparathyroidism
4 Feeding problems - -
5 Cleft palate Speech-language impairment Velopharyngeal insufficiency
6 - Developmental delay
Behavioural abnormalities
Learning difficulties
Behavioural abnormalities
7 Any comorbidities, 
e.g. anorectal 
malformation
Any comorbidities,
e.g. anorectal malformation
Any comorbidities,
e.g. anorectal malformation
8 Subtle facial 
dysmorphism
Subtle facial dysmorphism Subtle facial dysmorphism
* Individuals with two or more of the domains 1 - 8 should be considered for genetic testing for a possible 22q11.2 deletion 
(adapted from Óskarsdottir et al.[14]).
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sugges tive of a syndromic cause (e.g. hypo-
calcaemia or thymic aplasia). 
O scoring
Based on the diagnostic scoring guide for 
the consideration for genetic testing by 
Óskarsdottir et al.,[14] an assessment of the 
likelihood of a diagnosis of 22qDS was made 
in each patient. Each participant was given a 
score based on the presence of the number 
of clinical features suggestive of a 22qDS 
phenotype as classified in Table 1. The O 
score ranges from 1 to 8 depending on the 
number of clinical findings as suggested by 
the scoring system. The child’s age (infant, 
preschool or childhood-adolescence) was 
considered during the scoring process, as 
prominent presenting features of the syn-
drome are known to illustrate age-related 
penetrance. An O score equal to or above 2 
is taken as indicative of the need for formal 
FISH testing for the 22q11.2 deletion.
22q11.2 deletion FISH testing
The deletion status was determined 
by FISH testing using a fluorophore-
labelled locus-specific identifier TUPLE1 
probe, which hybridises to band q11.2 
on chromosome 22. FISH analysis was 
performed on metaphase spreads from 
standard lymphocyte cultures. Analysis was 
performed according to the  standardised 
procedure of the local diagnostic laboratory 
(National Health Laboratory Service, Cyto-
genetics Laboratory). To avoid additional 
venipuncture, where possible, blood for FISH 
analysis was drawn at the time of surgical or 
cardiac catheterisation procedures or when 
invasive sampling was required for routine 
work-up.
Ethical considerations
This study was approved by the Human Ethics 
Research Committee (HREC) of the Faculty 
of Health Sciences, University of Cape Town 
(UCT HREC no.: 204/2002). All patients who 
tested positive for 22qDS were referred for 
formal genetic counselling and managed in 
collaboration with a clinical geneticist. 
Results
Five hundred and eighty newly referred child-
ren with CHD were seen at the cardiology 
service at RCWMCH during the study 
period (Fig. 1). Of these, 191 patients met 
the inclusion criteria but for various reasons, 
including logistical and administrative 
(such as delayed return to RCWMCH from 
rural referral centres), only 150 patients 
could be enrolled into the study. Written 
informed consent was obtained subsequent 
to enrolment for 142 patients. None of the 
parents of the studied individuals reported 
a familial occurrence or positive family 
history.
Four patients died before a blood sample 
could be collected, the parents of two patients 
declined involvement in the study and for 
two patients, no parent or legal guardian 
could be identified to provide informed 
consent. A further 16 patients were lost 
to follow-up. Therefore only 125 patients 
were available for FISH testing. Based on 
our initial population estimate (of 1.7%) we 
predicted 2 - 3 FISH-positive results. 
Distribution of scores based on 
diagnostic guidelines
One hundred and twenty-five patients 
were O scored according to the clinical 
diagnostic guidelines provided in Table 1. 
The patients’ congenital cardiac anomaly 
was diagnosed by echocardiography and the 
specific lesion of each FISH-positive patient 
is summarised in Table 2. Dysmorphic 
features and extracardiac anomalies were 
based on documented findings from an 
evaluation performed by either a cardiologist 
or clinical geneticist. 
The results of the O scoring are summarised 
in Table 3. Since all participants had CHD, all 
125 patients had a baseline O score of 1. Eighty-
two patients had an isolated cardiovascular 
anomaly (score of 1), whereas 30 patients were 
found to have a cardiac anomaly plus one 
clinical feature in one of the remaining seven 
domains (score of 2), and 15 patients had a 
cardiac malformation and clinical features of 
two of the seven domains (score of 3). No 
patient had an O score of more than 3. 
Deletion frequency
22qDS FISH testing results were available 
for 125 samples of the 126 tested patients. 
580Total new patients
PTS meeting inclusion criteria
Total recruited
Patients consented
FISH tests done
1 test inconclusive
FISH tests completed
FISH tests negative 119 FISH tests positive 6 4.8%
125
126
142
150
191
Fig. 1. Summary of recruitment and enrolment of the 125 patients FISH tested for the 22qDS, with their 
results. The reasons for the marked attrition between patients meeting the inclusion criteria and those 
FISH tested are given in the text.
Table 2. Cardiac lesions of the six 22qDS 
(FISH-positive) patients
Diagnosis n
Ventricular septal defect 2
Tricuspid atresia and interrupted 
aortic arch
1
Tetralogy of Fallot with left aortic arch 1
Tricuspid atresia with right aortic arch 1
Ventricular septal defect with right 
aortic arch
1
Total 6
Table 3. Distribution of O scores among 
FISH-positive and FISH-negative 
patients. An O score of 2 or more 
suggests the need for FISH testing
FISH results
O score Negative Positive Totals
1 82 0 82
2 28 3 31
3   9 3 12
Total 119 6 125
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The result of one patient was technically inconclusive. Deletions at 
22q11.2 were detected in 6 of the remaining 125 patients (4.8% FISH-
positive: 2.8 times the previous rate of 1.7%). Deletions were seen in 
patients with one of three cardiac defects including tricuspid atresia 
and interrupted aortic arch, tricuspid atresia with right aortic arch, a 
ventricular septal defect with right aortic arch, an isolated ventricular 
septal defect, and a tetralogy of Fallot with a left aortic arch (Table 2). 
No FISH-positive cases were identified in the group of patients 
with an O score of 1, 6.7% of cases were found to be FISH positive in 
the group scoring 2 and 30.8% in the group within scoring category 3 
(Table 3). The mean score for FISH-positive cases was 2.7 and for 
FISH-negative cases 1.4, thereby justifying the FISH testing criterion 
of an O score of more than 2. 
However, 28 patients and 9 patients with scores of 2 and 3, 
respectively, were FISH negative. In other words, of the 43 patients 
who scored more than 2 (thereby indicating that FISH testing is 
warranted), only six were FISH positive. This gave the O scoring 
system a positive predictive value of only 15.9%, but a sensitivity of 
100%, meaning that none of the patients with an O score of less than 
2 were FISH positive. 
There remains the small possibility that patients with O scores 
>1, but non-FISH positive, are indeed deleted, due to the presence 
of a distal deletion,[16] or a smaller deletion that does not contain the 
TUPLE1 gene, or too small to be detected (<40kb). This speculation 
may be resolved with the use of the more sensitive screening probes, 
such as MLPA or SNPs. 
Discussion
This study was motivated by a concern that in our cardiac service, 
22qDS is clinically underdiagnosed, and this concern has been 
vindicated. Prospective FISH testing of all children with significant 
CHD has found a FISH-positive rate for 22qDS of 4.8% (6 patients) 
in 125 newly referred patients. This is 2.8 times the clinically detected 
rate of 1.7% found retrospectively in 2006. We have therefore shown 
that 22qDS had been clinically under-recognised by almost threefold 
in patients presenting to our cardiac service. Speculation around the 
reasons for this is difficult, but the lack of the characteristic facial 
features of 22qDS in our patients may be contributory. 
The Óskarsdottir scoring system was developed in Sweden.[14] 
In contrast, our patient population is predominantly non-white, 
nearly always lacking the obvious dysmorphic facial features that we 
have come to associate with white FISH-positive patients. We are 
currently unsure if this phenotypic variation extends to the other 
typically described phenotypic characteristics of 22qDS, and a review 
is currently underway of all our FISH-positive patients to assess this. 
The cardiac lesions in this cohort of FISH-positive patients (Table 2) 
are all known to occur in 22qDS, but the number is too small to draw 
firm conclusions from these limited findings to assist in developing 
changes to clinical recognition models. It is worth noting, however, 
that two patients had isolated ventricular septal defects (VSDs), 
which are not conotruncal lesions. Had FISH testing been performed 
only on patients with conotruncal lesions, these two cases would not 
have been detected. 
Óskarsdottir et al.[14] suggested that a score of 2 or more indicates 
the need for formal FISH testing. O scoring of our cohort had a 
positive predictive value of only 14%, emphasising the difficulty in 
clinical recognition of our patients with this syndrome. Whereas the 
international scoring schedule for the 22qDS is poorly predictive for 
FISH testing in the southern African context, it is highly sensitive in 
suggesting those that do not require testing: an O score of 1 always 
predicted a negative FISH test correctly. Therefore the O score is of 
limited aid in the diagnosis of the syndrome in our local population, 
but remains a robust tool to suggest refraining from testing those 
with too low an O score.
The need for a firm diagnosis is important since it carries several 
serious implications[17] including, inter alia, cascade screening of 
parents and family for the deletion, a focused search for known 
comorbidities, the need for irradiated blood for cardiopulmonary 
bypass or blood transfusion, assessment for immunodeficiency and 
hypocalcaemia, and counselling with regard to potential future 
problems, such as learning difficulties and schizophrenia.[17] It is 
therefore important that a high index of suspicion is maintained for 
this syndrome. Until a local recognition tool is developed, clinicians 
should apply all recognition criteria liberally to suggest the need 
for FISH testing, particularly in non-white patients. To reduce the 
cost of too many needless FISH tests, we have to define the cardinal 
phenotypic features of 22qDS in our patient population more clearly; 
such a study is currently underway.
Study limitations
The study suffered from several logistical problems, mostly related 
to the nature of clinical healthcare delivery in a resource-constrained 
environment, including significant loss to follow-up and referral 
from distant rural healthcare centres limiting participation in the 
study. Although several attempts were made to enroll missed patients 
if a follow-up visit occurred during the study period, 41 cases were 
missed as a result of the genetic counsellor being unable to approach 
the family before the patient was discharged from the hospital. No 
FISH-positive white children were detected in this cohort. 
Conclusions
If patients in a South African setting are selected for FISH testing for 
the 22qDS on clinical suspicion only, the disorder will be severely 
under-diagnosed. We have shown by prospective testing that the 
prevalence of the disorder may be nearly three times higher than 
clinically suspected in a population with CHD referred to the 
PCSWC tertiary cardiology unit. This may be owing to the fact that 
the international clinical scoring system currently in use may not 
be applicable to our patient population. The reasons for this are not 
clear, but are currently under investigation. 
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Fig. 2. Subtle 22qDS facial dysmorphism typical of our non-white patient 
population. Patient images provided with the consent of their parents or legal 
guardians.
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